SARAH CREVISTON

Report language for Labor HHS Annual Appropriations BillHR 3613: Part D Beneficiary Appeals Fairness Act - Amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. Medicare Part B Drug Reimbursement. H.R. 8 American Taxpayer Relief Act of 2012 -- working to mitigate the impact to kidney patients of the payment reductions required by the Act. HR 3306: Telehealth Enhancement Act of 2013.

HR 1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intraveneous immune globulin (IVIG) in a patient's home for the treatment of primary immunde deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. HR 5597: To establish a Medicare patient IVIG access demonstration project HR 4994-Medicare and Medicaid Extenders Act of 2010: To establish a Medicare patient IVIG access demonstration project S 701-Medicare Patient IVIG Access Act of 2009 HR 1586-Education, Jobs and Medicaid funding bill as it relates to Medicaid AMP

H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R. 5597: To establish a Medicare patient IVIG access demonstration project S.701: Medicare Patient IVIG Access Act of 2009 H.R. 1586: Education, Jobs and Medicaid funding bill as it relates to Medicaid AMP

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending. H.R. 4872: The Health Care and Education Reconciliation Act. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). S. 1796/H.R. 3200: America's Healthy Future Act, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices.

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending. H.R. 4872: The Health Care and Education Reconciliation Act. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R. 5597: To establish a Medicare patient IVIG access demonstration project H.R. 4899: Small Business and Infrastructure Jobs Tax Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs. H.R. 4213: American Jobs and Closing Tax Loopholes Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs, changes to 340B drug discount program and international tax provisions and research and development tax credits. H.R. 4846: Bleeding Disorder Screening, Awareness, and Further Education (SAFE) Act of 2010 S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). S. 1796/H.R. 3200: America's Healthy Future Act, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices.

H.R. 3200/S. 1796: To provide affordable, quality health care for all Americand and reduce the growth in health care spending. H.R. 3590: The Patient Protection Affordable Care Act. H.R. 4872: The Health Care and Education Reconciliation Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. 340B drug discount program Drug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200/S. 1796: To provide affordable, quality health care for all Americand and reduce the growth in health care spending. H.R. 3590: The Patient Protection Affordable Care Act. H.R. 4872: The Health Care and Education Reconciliation Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R. 4899: Supplemental Appropriations Act, 2010, specific focus on Health and Human Services Funding H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. 340B drug discount program Drug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending. H.R. 4872: The Health Care and Education Reconciliation Act. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R. 5597: To establish a Medicare patient IVIG access demonstration project H.R. 4899: Small Business and Infrastructure Jobs Tax Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs. H.R. 4213: American Jobs and Closing Tax Loopholes Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs, changes to 340B drug discount program and international tax provisions and research and development tax credits. H.R. 4846: Bleeding Disorder Screening, Awareness, and Further Education (SAFE) Act of 2010 S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). S. 1796/H.R. 3200: America's Healthy Future Act, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices.

H.R. 3200/S. 1796: To provide affordable, quality health care for all Americand and reduce the growth in health care spending. H.R. 3590: The Patient Protection Affordable Care Act. H.R. 4872: The Health Care and Education Reconciliation Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R. 4899: Supplemental Appropriations Act, 2010, specific focus on Health and Human Services Funding H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. 340B drug discount program Drug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200/S. 1796: To provide affordable, quality health care for all Americand and reduce the growth in health care spending. H.R. 3590: The Patient Protection Affordable Care Act. H.R. 4872: The Health Care and Education Reconciliation Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. 340B drug discount program Drug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending. H.R. 4872: The Health Care and Education Reconciliation Act. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). S. 1796/H.R. 3200: America's Healthy Future Act, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices.

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending. H.R. 4872: The Health Care and Education Reconciliation Act. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R. 5597: To establish a Medicare patient IVIG access demonstration project H.R. 4899: Small Business and Infrastructure Jobs Tax Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs. H.R. 4213: American Jobs and Closing Tax Loopholes Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs, changes to 340B drug discount program and international tax provisions and research and development tax credits. H.R. 4846: Bleeding Disorder Screening, Awareness, and Further Education (SAFE) Act of 2010 S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). S. 1796/H.R. 3200: America's Healthy Future Act, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices.

HR 1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intraveneous immune globulin (IVIG) in a patient's home for the treatment of primary immunde deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. HR 5597: To establish a Medicare patient IVIG access demonstration project HR 4994-Medicare and Medicaid Extenders Act of 2010: To establish a Medicare patient IVIG access demonstration project S 701-Medicare Patient IVIG Access Act of 2009 HR 1586-Education, Jobs and Medicaid funding bill as it relates to Medicaid AMP

H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R. 5597: To establish a Medicare patient IVIG access demonstration project S.701: Medicare Patient IVIG Access Act of 2009 H.R. 1586: Education, Jobs and Medicaid funding bill as it relates to Medicaid AMP

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending. H.R. 4872: The Health Care and Education Reconciliation Act. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R. 5597: To establish a Medicare patient IVIG access demonstration project H.R. 4899: Small Business and Infrastructure Jobs Tax Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs. H.R. 4213: American Jobs and Closing Tax Loopholes Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs, changes to 340B drug discount program and international tax provisions and research and development tax credits. H.R. 4846: Bleeding Disorder Screening, Awareness, and Further Education (SAFE) Act of 2010 S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). S. 1796/H.R. 3200: America's Healthy Future Act, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices.

HR 1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intraveneous immune globulin (IVIG) in a patient's home for the treatment of primary immunde deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. HR 5597: To establish a Medicare patient IVIG access demonstration project HR 4994-Medicare and Medicaid Extenders Act of 2010: To establish a Medicare patient IVIG access demonstration project S 701-Medicare Patient IVIG Access Act of 2009 HR 1586-Education, Jobs and Medicaid funding bill as it relates to Medicaid AMP

H.R. 3200/S. 1796: To provide affordable, quality health care for all Americand and reduce the growth in health care spending. H.R. 3590: The Patient Protection Affordable Care Act. H.R. 4872: The Health Care and Education Reconciliation Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R. 4899: Supplemental Appropriations Act, 2010, specific focus on Health and Human Services Funding H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. 340B drug discount program Drug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. H.R. 4213: American Jobs and Closing Tax Loopholes Act of 2010, provisions relating to 340B 340B drug discount program 510(k) approval for medical devicesDrug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200/S. 1796: To provide affordable, quality health care for all Americand and reduce the growth in health care spending. H.R. 3590: The Patient Protection Affordable Care Act. H.R. 4872: The Health Care and Education Reconciliation Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. 340B drug discount program Drug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200/S. 1796: To provide affordable, quality health care for all Americand and reduce the growth in health care spending. H.R. 3590: The Patient Protection Affordable Care Act. H.R. 4872: The Health Care and Education Reconciliation Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R. 4899: Supplemental Appropriations Act, 2010, specific focus on Health and Human Services Funding H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. 340B drug discount program Drug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending. H.R. 4872: The Health Care and Education Reconciliation Act. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R. 5597: To establish a Medicare patient IVIG access demonstration project H.R. 4899: Small Business and Infrastructure Jobs Tax Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs. H.R. 4213: American Jobs and Closing Tax Loopholes Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs, changes to 340B drug discount program and international tax provisions and research and development tax credits. H.R. 4846: Bleeding Disorder Screening, Awareness, and Further Education (SAFE) Act of 2010 S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). S. 1796/H.R. 3200: America's Healthy Future Act, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices.

H.R. 3200/S. 1796: To provide affordable, quality health care for all Americand and reduce the growth in health care spending. H.R. 3590: The Patient Protection Affordable Care Act. H.R. 4872: The Health Care and Education Reconciliation Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. 340B drug discount program Drug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending. H.R. 4872: The Health Care and Education Reconciliation Act. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). S. 1796/H.R. 3200: America's Healthy Future Act, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices.

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending. H.R. 4872: The Health Care and Education Reconciliation Act. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). S. 1796/H.R. 3200: America's Healthy Future Act, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices.

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending. H.R. 4872: The Health Care and Education Reconciliation Act. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R. 5597: To establish a Medicare patient IVIG access demonstration project H.R. 4899: Small Business and Infrastructure Jobs Tax Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs. H.R. 4213: American Jobs and Closing Tax Loopholes Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs, changes to 340B drug discount program and international tax provisions and research and development tax credits. H.R. 4846: Bleeding Disorder Screening, Awareness, and Further Education (SAFE) Act of 2010 S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). S. 1796/H.R. 3200: America's Healthy Future Act, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices.

H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R. 5597: To establish a Medicare patient IVIG access demonstration project S.701: Medicare Patient IVIG Access Act of 2009 H.R. 1586: Education, Jobs and Medicaid funding bill as it relates to Medicaid AMP

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending. H.R. 4872: The Health Care and Education Reconciliation Act. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R. 5597: To establish a Medicare patient IVIG access demonstration project H.R. 4899: Small Business and Infrastructure Jobs Tax Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs. H.R. 4213: American Jobs and Closing Tax Loopholes Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs, changes to 340B drug discount program and international tax provisions and research and development tax credits. H.R. 4846: Bleeding Disorder Screening, Awareness, and Further Education (SAFE) Act of 2010 S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). S. 1796/H.R. 3200: America's Healthy Future Act, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices.

HR 1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intraveneous immune globulin (IVIG) in a patient's home for the treatment of primary immunde deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. HR 5597: To establish a Medicare patient IVIG access demonstration project HR 4994-Medicare and Medicaid Extenders Act of 2010: To establish a Medicare patient IVIG access demonstration project S 701-Medicare Patient IVIG Access Act of 2009 HR 1586-Education, Jobs and Medicaid funding bill as it relates to Medicaid AMP

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending. H.R. 4872: The Health Care and Education Reconciliation Act. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). S. 1796/H.R. 3200: America's Healthy Future Act, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices.

H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R. 5597: To establish a Medicare patient IVIG access demonstration project S.701: Medicare Patient IVIG Access Act of 2009 H.R. 1586: Education, Jobs and Medicaid funding bill as it relates to Medicaid AMP

HR 1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intraveneous immune globulin (IVIG) in a patient's home for the treatment of primary immunde deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. HR 5597: To establish a Medicare patient IVIG access demonstration project HR 4994-Medicare and Medicaid Extenders Act of 2010: To establish a Medicare patient IVIG access demonstration project S 701-Medicare Patient IVIG Access Act of 2009 HR 1586-Education, Jobs and Medicaid funding bill as it relates to Medicaid AMP

H.R. 3200/S. 1796: To provide affordable, quality health care for all Americand and reduce the growth in health care spending. H.R. 3590: The Patient Protection Affordable Care Act. H.R. 4872: The Health Care and Education Reconciliation Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. 340B drug discount program Drug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200/S. 1796: To provide affordable, quality health care for all Americand and reduce the growth in health care spending. H.R. 3590: The Patient Protection Affordable Care Act. H.R. 4872: The Health Care and Education Reconciliation Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R. 4899: Supplemental Appropriations Act, 2010, specific focus on Health and Human Services Funding H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. 340B drug discount program Drug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200/S. 1796: To provide affordable, quality health care for all Americand and reduce the growth in health care spending. H.R. 3590: The Patient Protection Affordable Care Act. H.R. 4872: The Health Care and Education Reconciliation Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R. 4899: Supplemental Appropriations Act, 2010, specific focus on Health and Human Services Funding H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. 340B drug discount program Drug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200/S. 1796: To provide affordable, quality health care for all Americand and reduce the growth in health care spending. H.R. 3590: The Patient Protection Affordable Care Act. H.R. 4872: The Health Care and Education Reconciliation Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. 340B drug discount program Drug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200/S. 1796: To provide affordable, quality health care for all Americand and reduce the growth in health care spending. H.R. 3590: The Patient Protection Affordable Care Act. H.R. 4872: The Health Care and Education Reconciliation Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R. 4899: Supplemental Appropriations Act, 2010, specific focus on Health and Human Services Funding H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. 340B drug discount program Drug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending. H.R. 4872: The Health Care and Education Reconciliation Act. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). S. 1796/H.R. 3200: America's Healthy Future Act, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices.

H.R. 3200/S. 1796: To provide affordable, quality health care for all Americand and reduce the growth in health care spending. H.R. 3590: The Patient Protection Affordable Care Act. H.R. 4872: The Health Care and Education Reconciliation Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. 340B drug discount program Drug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending. H.R. 4872: The Health Care and Education Reconciliation Act. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R. 5597: To establish a Medicare patient IVIG access demonstration project H.R. 4899: Small Business and Infrastructure Jobs Tax Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs. H.R. 4213: American Jobs and Closing Tax Loopholes Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs, changes to 340B drug discount program and international tax provisions and research and development tax credits. H.R. 4846: Bleeding Disorder Screening, Awareness, and Further Education (SAFE) Act of 2010 S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). S. 1796/H.R. 3200: America's Healthy Future Act, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices.

H.R. 3200/S. 1796: To provide affordable, quality health care for all Americand and reduce the growth in health care spending. H.R. 3590: The Patient Protection Affordable Care Act. H.R. 4872: The Health Care and Education Reconciliation Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R. 4899: Supplemental Appropriations Act, 2010, specific focus on Health and Human Services Funding H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. 340B drug discount program Drug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200/S. 1796: To provide affordable, quality health care for all Americand and reduce the growth in health care spending. H.R. 3590: The Patient Protection Affordable Care Act. H.R. 4872: The Health Care and Education Reconciliation Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R. 4899: Supplemental Appropriations Act, 2010, specific focus on Health and Human Services Funding H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. 340B drug discount program Drug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200/S. 1796: To provide affordable, quality health care for all Americand and reduce the growth in health care spending. H.R. 3590: The Patient Protection Affordable Care Act. H.R. 4872: The Health Care and Education Reconciliation Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. 340B drug discount program Drug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. H.R. 4213: American Jobs and Closing Tax Loopholes Act of 2010, provisions relating to 340B 340B drug discount program 510(k) approval for medical devicesDrug and device marketing and promotion Drug and biological product pricing and reimbursement Follow-on biologics Healthcare-acquired infections Health insurance reform Implementation of bundling provisions in H.R. 6331(110th Congress) Issues regarding 340B Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans Drug and device marketing and promotion Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans Drug and device marketing and promotion Drug and biological product pricing and reimbursement Healthcare-acquired infections Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans. Drug and biological product pricing and reimbursement Product Payment Issues Therapy Payment Issues

H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans. Drug and biological product pricing and reimbursement Product Payment Issues Therapy Payment Issues

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. H.R.2502 : To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes. S. 1679: An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. Drug and device marketing and promotion Drug and biological product pricing and reimbursement Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. H.R.2502 : To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes. S. 1679: An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. Drug and device marketing and promotion Drug and biological product pricing and reimbursement Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

S.515/S. 610/H.R. 1260: Patent Reform Act of 2009, all issues related to patent reform.

S.515/H.R. 1260: Patent Reform Act of 2009

S.515/S. 610/H.R. 1260: Patent Reform Act of 2009, all issues related to patent reform.

S.515/S. 610/H.R. 1260: Patent Reform Act of 2009, all issues related to patent reform.

S.515/H.R. 1260: Patent Reform Act of 2009

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. H.R.2502 : To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes. S. 1679: An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. Drug and device marketing and promotion Drug and biological product pricing and reimbursement Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. H.R.2502 : To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes. S. 1679: An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. Drug and device marketing and promotion Drug and biological product pricing and reimbursement Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans. Drug and biological product pricing and reimbursement Product Payment Issues Therapy Payment Issues

H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans. Drug and biological product pricing and reimbursement Product Payment Issues Therapy Payment Issues

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans Drug and device marketing and promotion Drug and biological product pricing and reimbursement Healthcare-acquired infections Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans Drug and device marketing and promotion Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans. Drug and biological product pricing and reimbursement Product Payment Issues Therapy Payment Issues

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. Product Payment Issues Therapy Payment Issues

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. Product Payment Issues Therapy Payment Issues

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans Drug and device marketing and promotion Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans Drug and device marketing and promotion Drug and biological product pricing and reimbursement Healthcare-acquired infections Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans. Drug and biological product pricing and reimbursement Product Payment Issues Therapy Payment Issues

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. Product Payment Issues Therapy Payment Issues

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. H.R.2502 : To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes. S. 1679: An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. Drug and device marketing and promotion Drug and biological product pricing and reimbursement Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. H.R.2502 : To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes. S. 1679: An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. Drug and device marketing and promotion Drug and biological product pricing and reimbursement Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 3590: An act entitled The Patient Protection and Affordable Care Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. S. 1679: An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. S. 1796, "America's Healthy Future Act," An original bill to provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. Drug and device marketing and promotion Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. Product Payment Issues Therapy Payment Issues

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. Product Payment Issues Therapy Payment Issues

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. Product Payment Issues Therapy Payment Issues

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. H.R.2502 : To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes. S. 1679: An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. Drug and device marketing and promotion Drug and biological product pricing and reimbursement Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 3590: An act entitled The Patient Protection and Affordable Care Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. S. 1679: An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. S. 1796, "America's Healthy Future Act," An original bill to provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. Drug and device marketing and promotion Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. H.R.2502 : To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes. S. 1679: An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. Drug and device marketing and promotion Drug and biological product pricing and reimbursement Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. H.R.2502 : To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes. S. 1679: An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. Drug and device marketing and promotion Drug and biological product pricing and reimbursement Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. H.R.2502 : To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes. S. 1679: An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. Drug and device marketing and promotion Drug and biological product pricing and reimbursement Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 3590: An act entitled The Patient Protection and Affordable Care Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. S. 1679: An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. S. 1796, "America's Healthy Future Act," An original bill to provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. Drug and device marketing and promotion Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 3590: An act entitled The Patient Protection and Affordable Care Act. H.R. 3962: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. S. 1679: An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. S. 1796, "America's Healthy Future Act," An original bill to provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. Drug and device marketing and promotion Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. Product Payment Issues Therapy Payment Issues

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. Product Payment Issues Therapy Payment Issues

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. Product Payment Issues Therapy Payment Issues

H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans. Drug and biological product pricing and reimbursement Product Payment Issues Therapy Payment Issues

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. H.R.2502 : To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes. S. 1679: An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. Drug and device marketing and promotion Drug and biological product pricing and reimbursement Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans Drug and device marketing and promotion Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans. Drug and biological product pricing and reimbursement Product Payment Issues Therapy Payment Issues

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R. 2726: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. H.R.2502 : To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes. S. 1679: An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree. "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. Drug and device marketing and promotion Drug and biological product pricing and reimbursement Drug and biological product pricing and reimbursement Healthcare-acquired infections Issues regarding 340B Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans. Drug and biological product pricing and reimbursement Product Payment Issues Therapy Payment Issues

H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans Drug and device marketing and promotion Drug and biological product pricing and reimbursement Healthcare-acquired infections Lifetime caps for insurance Medical product safety Prescription drug pedigree and anti-counterfeiting policy

S.515/S. 610/H.R. 1260: Patent Reform Act of 2009, all issues related to patent reform.

S.515/H.R. 1260: Patent Reform Act of 2009

S.515/H.R. 1260: Patent Reform Act of 2009

S.515/S. 610/H.R. 1260: Patent Reform Act of 2009, all issues related to patent reform.

S.515/S. 610/H.R. 1260: Patent Reform Act of 2009, all issues related to patent reform.

H.R.1: The American Recovery and Reinvestment Act (stimulus bill); Specifically focused on aspects of the bill related to comparative effectiveness research. H.R.1548 : To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S.547 : A bill to amend title XIX of the Social Security Act to reduce the costs of prescription drugs for enrollees of Medicaid managed care organizations by extending the discounts offered under fee-for-service Medicaid to such organizations. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R.1085/S. 442: To impose a limitation on lifetime aggregate limits imposed by health plans. Drug and biological product pricing and reimbursement Product Payment Issues Therapy Payment Issues